Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

NCT05897294 | Unknown

• 1 other identifier: TFF-VE-001
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks. Duration of treatment may be extended on a case-by-case basis depending on drug availability and after discussion with the Sponsor.

Conditions

Invasive Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis; Chronic Pulmonary Aspergillosis; Aspergillus Tracheobronchitis; Anastomotic Infection; Pulmonary Fungal Infection

Keywords

voriconazole; Pulmonary Aspergillosis

Interventions

Voriconazole Inhalation Powder DRUG

dry powder inhalation of voriconazole

Also known as: TFF VORI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged 18 years or older at screening.
• Diagnosed with pulmonary aspergillosis including Invasive Pulmonary Aspergillosis (IPA), Chronic Pulmonary Aspergillosis (CPA), Allergic Bronchopulmonary Aspergillosis (ABPA), Aspergillus tracheobronchitis and Aspergillus bronchial anastomotic infection. Pulmonary infections with voriconazole sensitive fungi other than Aspergillus such as but not limited to scedosporium and fusarium are also allowed.
• Patient has limited or no treatment options due to documented or anticipated intolerance, toxicity, contraindications, or lack of clinical response to SOC antifungal therapy, as advocated by the relevant regional treatment guidelines.
• The treating clinician considers that the potential advantage of using Voriconazole Inhalation Powder outweighs the potential risks. In patients with disseminated fungal infection in addition to pulmonary infection, Voriconazole Inhalation Powder must be used as add-on therapy to the current SOC.
• The Sponsor agrees that the benefit:risk assessment is favorable for the use of Voriconazole Inhalation Powder in the patient.
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test (UPT) prior to first dose. Sexually active WOCBP and male patients must agree to use highly effective birth control or abstinence until 3 months after last dose.
• Patient succeeds in meeting training criteria on the use of the dry powder inhaler (DPI) and is willing and able to perform adequate inhalation technique for treatment duration in the opinion of the treating clinician or designee.
• Patient provides informed consent and agrees to follow the treatment regimen and safety and outcomes assessments.

You may not qualify if:

• Infection with fungi not responsive to voriconazole.
• Pregnant or breastfeeding.
• History or presence of hypersensitivity or idiosyncratic reaction to voriconazole or excipients in Voriconazole Inhalation Powder.
• Patients with severe liver disease as defined by Child-Pugh Class C.
• Patients who are eligible and are able to participate in a clinical trial of Voriconazole Inhalation Powder.

Sponsors & Collaborators

• TFF Pharmaceuticals, Inc.: lead

MeSH Terms

Conditions

Invasive Pulmonary Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Lung Diseases, Fungal; Pulmonary Aspergillosis

Condition Hierarchy (Ancestors)

Aspergillosis; Mycoses; Bacterial Infections and Mycoses; Infections; Invasive Fungal Infections; Lung Diseases; Respiratory Tract Diseases; Respiratory Tract Infections; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2023
• First Posted: June 9, 2023
• Last Updated: November 21, 2024

Record last verified: 2024-11